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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) isolates (n = 216), collected between January 1999 and
May 2003 in a tertiary-care university hospital in Guadalajara, Mexico, were characterised by
antibiotype, pulsed-ﬁeld gel electrophoresis (PFGE) of SmaI macrorestriction fragments, and hybridi-
sation of ClaI digests with mecA- and Tn554-speciﬁc DNA probes. Representatives of the single clonal
type found were analysed by spa typing, multilocus sequence typing and staphylococcal chromosomal
cassette mec (SCCmec) typing, and were tested for the presence of 22 virulence determinants and agr
type. A single PFGE pattern was identiﬁed, with minor variations over time, with spa type 2, sequence
type 5, SCCmec type II, agr type 2 and the presence of the enterotoxin genes seg and sei, the c-haemolysin
variant gene hlg-v and the leukocidin lukE–lukD genes. In addition, the isolates showed antimicrobial
resistance to b-lactams, macrolides, chloramphenicol and imipenem, and susceptibility to gentamicin,
rifampicin, trimethoprim–sulphamethoxazole and vancomycin. Following its appearance in 1997, this
clone spread within the hospital, and is now present in most of the hospital units and wards.
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INTRODUCTION
Staphylococcus aureus is a major human pathogen
responsible for a wide spectrum of diseases,
including skin infections, septicaemia, pneu-
monia, and wound, bone and joint infections.
Because of its intrinsic virulence, its ability to
cause a diverse array of life-threatening infec-
tions, and its capacity to adapt to different
environmental conditions, this organism consti-
tutes a serious public health burden, not only in
the hospital environment, but also in the commu-
nity setting. Methicillin-resistant Staphylococcus
aureus (MRSA) was ﬁrst detected in Europe in
1961, soon after the introduction of methicillin.
Subsequently, epidemic strains of MRSA have
emerged worldwide [1]. The combination of
several molecular techniques has allowed insights
into the evolutionary process that led to the
emergence and spread of just a few pandemic
clones of MRSA [2–4]. Recently, it has been
demonstrated that the proportion of patients for
whom death is attributable to MRSA is signiﬁ-
cantly higher than that for methicillin-susceptible
S. aureus (MSSA), with a strong statistical trend
for death associated with nosocomial MRSA
infection and bacteraemia compared with MSSA
[5]. In Mexico, MRSA was an uncommon nosoco-
mial pathogen until the 1990s [6–8]. Surveillance
studies performed in several Latin American
countries, including Mexico, have now reported
a high occurrence of MRSA in commonly
observed infections, and a marked geographical
variation in multiresistance patterns [6,8].
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Although S. aureus is considered to be an
opportunistic pathogen, it has been suggested
that, essentially, any S. aureus genotype can
become a life-threatening human pathogen, but
that strains from some clonal lineages are more
virulent than others [9]. S. aureus produces a wide
variety of toxins, including the staphylococcal
enterotoxins (SEs) A–E and G–J, enterotoxin
homologues (SEK, SEL, SEP, SEM and SEO), the
toxic shock syndrome toxin-1 (TSST-1), the exfo-
liative toxins (ETs) A, B and D, several haemo-
lysins (a, b, c and d) and leukocidins. These toxins
were described initially as being responsible for
speciﬁc acute staphylococcal toxaemia syn-
dromes, such as toxic shock syndrome and
staphylococcal scarlet fever (both caused by
TSST-1, SEB and SEC), scalded skin syndrome
(caused by the ETs), and staphylococcal food
poisoning (caused by the SEs) [10]. Panton–
Valentine leukocidin is a toxin associated with
skin infections (furuncles), community-acquired
MRSA infections and necrotising pneumonia
[11]. Expression of most virulence factors is
controlled by the accessory gene regulator (agr)
locus, which encodes a two-component signalling
pathway, whose activating ligand is a bacterial
density-sensing peptide also encoded by agr [12];
different alleles of agr are classiﬁed into four types
(1–4).
The aim of the present study was to character-
ise the MRSA strains isolated from 1999 to
mid-2003 in a tertiary-care academic hospital in
Guadalajara, Jalisco, Mexico, by various mole-
cular typing methods, including pulsed-ﬁeld gel
electrophoresis (PFGE), spa typing, multilocus
sequence typing (MLST), and staphylococcal
cassette chromosome mec (SCCmec) typing. Addi-
tionally, the presence of several staphylococcal
virulence determinants and the accessory gene
regulator (agr) group was investigated.
MATERIALS AND METHODS
Hospital setting
The Hospital Civil de Guadalajara ‘Fray Antonio Alcalde’
(Jalisco, Me´xico) is a 707-bed tertiary-care teaching hospital
with 549 adult and 158 paediatric beds, distributed in 31 wards
in two connected buildings. All the paediatric units are located
in one building, with the adult services distributed between
the two buildings. The hospital serves the population of the
greater Guadalajara metropolitan area, which is the second
largest city in Mexico and has 3 641 847 inhabitants. The
hospital also serves the rest of the state of Jalisco (population
7 000 000) and three neighbouring western states: Michoacan,
Nayarit and Zacatecas (total combined population of
6 259 462). The number of MRSA infections in the hospital
increased signiﬁcantly between 1999 and 2003 (52 cases in
1999, 101 in 2000, 232 in 2001, 219 in 2002, and 235 in 2003).
Bacterial strains
In total, 839 MRSA isolates from individual patients (746
adults, age range 18–85 years; 93 paediatric patients, age range
1 month to 12 years) were collected between January 1999 and
May 2003. Efforts were made to maximise the likelihood that
the collection of isolates selected for the molecular characteri-
sation reﬂected the composition of the MRSA ﬂora in the
hospital during the period of the study. For this reason, 216
(26%) isolates representing different years, hospital wards and
infection sites were included in the study. The selected isolates
were from patients on a range of adult (intensive care unit,
mixed medical–surgical unit, trauma unit, surgery, internal
medicine, nephrology and cardiopulmonary) and paediatric
(paediatric and newborn intensive care units and paediatric
surgery) wards. Of the 216 MRSA isolates, 197 were from
adults and 19 were from children; 77 were from blood cultures,
62 from catheter-related infections, 46 from wound samples, 20
from pleural ﬂuid, seven from cerebrospinal ﬂuid, and four
from abscesses. All were identiﬁed as S. aureus by their ability
to coagulate citrated rabbit plasma (BD Difco, Franklin Lakes,
NJ, USA).
Antimicrobial susceptibility tests
Susceptibilities were determined by the automated MicroScan
method (Dade-Behring, Sacramento, CA, USA) for penicillin,
oxacillin, amoxycillin, cefotaxime, cephalothin, cefazolin,
imipenem, trimethoprim–sulphamethoxazole, ciproﬂoxacin,
chloramphenicol, clindamycin, erythromycin, clarithromycin,
gentamicin, rifampicin, tetracycline and vancomycin. Suscep-
tibility to vancomycin was also determined by broth microdi-
lution following NCCLS guidelines [13]. The isolates were
conﬁrmed as MRSA by hybridisation with a mecA probe [14].
DNA isolation for PCR
Chromosomal DNA was extracted by incubating cells grown
overnight on solid medium in 20 lL of TE (10 mM Tris, 1 mM
EDTA, pH 8) with lysostaphin 0.5 mg ⁄mL for 30 min, and
then denaturing for 15 min at 95C. The cell debris was
removed by centrifugation at 13 000 g for 5 min, and 2 lL of
the supernatant was used as the DNA template in PCRs.
Molecular typing
The genetic background of the MRSA isolates was investigated
by PFGE of SmaI digests of chromosomal DNA, followed by
hybridisation with a Tn554 probe as described previously [15];
spa typing and MLST were also performed for a selection of
isolates as described previously [16,17]. Brieﬂy, spa typing is
based on sequencing the polymorphic region of protein A, a
superantigen of S. aureus, while MLST is based on sequencing
internal fragments of seven housekeeping genes (arc, aroE,
glpF, gmk, pta, tpi and yqiL); for each isolate, the alleles at the
seven loci deﬁned the allelic proﬁle, which corresponded to a
sequence type (ST). ST designations were those assigned by
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the MLST database (http://www.mlst.net). For spa typing and
MLST, sequences of both strands were determined by Macro-
gen (Seoul, South Korea). The relatedness among PFGE
proﬁles was evaluated with BioNumerics software (Applied
Maths, Ghent, Belgium).
Detection of accessory genes by PCR
The agr allele group (1–4) [12], the SCCmec type (I–IV,
according to the designation of Oliveira and de Lencastre
[18]), and sequences speciﬁc for the genes encoding SEs A–E
and G–J, as well as TSST-1 [19], were detected by multiplex
PCR strategies. The b, c and c-variant haemolysins, ETs A, B
and D, Panton–Valentine leukocidin LukE–LukD, and the
epidermal cell differentiation inhibitor exotoxin, were detected
as described previously [11,12]. All PCR products were
analysed by electrophoresis on agarose 1% w ⁄v gels.
The following reference strains from the collection of the
Laboratory of Molecular Genetics at Instituto de Tecnologia
Quı´mica e Biolo´gica da Universidade Nova de Lisboa (Oeiras,
Portugal) were also used in this study: NCTC8325, New
York ⁄ Japan clone isolate BK2464, EMRSA-16 from the UK, the
Iberian clone isolate HPV107, the Brazilian clone isolate HU25,
and the Mexican clone isolate 78MEXC.
RESULTS
Antimicrobial susceptibility
All 216 isolates were resistant to penicillin, oxacil-
lin, amoxycillin, cefotaxime, cephalothin, cefazo-
lin, imipenem, ciproﬂoxacin, chloramphenicol,
clindamycin, erythromycin and clarithromycin.
None of the isolates was resistant to gentamicin,
trimethoprim–sulphamethoxazole, rifampicin or
vancomycin, and only two isolates showed resist-
ance to tetracycline. All MRSA isolates in 1998 had
a vancomycin MIC of 0.5 mg ⁄L, but the propor-
tion of isolates with an MIC of 2 mg ⁄L increased
gradually to 12% in 1999, 30% in 2000, 78% in
2001, and 100% from 2002 onwards (comparison
of proportions: v2 405.49; p 0.000001).
MRSA isolates
In 1999, MRSA was found in 17 units, of which 13
(76%) were adult services. At the end of 2003,
MRSA was found in 27 units, of which 20 (74%)
were adult services. The adult services with a
large proportion of MRSA isolates included the
intensive care unit, a mixed medical–surgical
unit, the trauma unit, surgery, internal medicine,
nephrology and the cardiopulmonary service. The
paediatric wards with MRSA isolates were the
paediatric and newborn intensive care units, and
the paediatric surgery ward.
Molecular typing
PFGE analysis identiﬁed a single PFGE pattern,
designated pattern A, that included 215 of the 216
MRSA isolates, with 18 subtypes (A1–A18) that
differed in up to six band positions. The remain-
ing isolate had an unrelated PFGE pattern (more
than six band differences) (Fig. 1). Representa-
tives of clone A were compared to strains belong-
ing to international MRSA clones characterised
previously, namely EMRSA-16 (ST36-SCCmec II),
and the New York ⁄ Japan (ST5-II), the Iberian
(ST247-IA) and the Brazilian (ST239-III) clones.
Clone A showed a high degree of similarity to
the New York ⁄ Japan clone (Fig. 2).
All MRSA isolates analysed had two copies of
Tn554 in SmaI fragments of c. 646 and 200 kb
(results not shown), which concurs with the two
copies of Tn554 present in isolates belonging to
the New York ⁄ Japan clone [20]. The character-
isation by spa typing, MLST and SCCmec typing
of representatives of clone A demonstrated
that isolates in this clone were spa type 2
(TJMBMDMGMK), ST5 and SCCmec type II
(Table 1).
When representatives of clone A were tested
for the presence of 22 virulence determinants,
only the genes encoding enterotoxins G (seg) and I
(sei), the c-haemolysin variant (hlg-v) and leuko-
cidin LukE–LukD (lukE–lukD) were detected.
Clone A belonged to agr type 2 (Table 1).
DISCUSSION
Soon after methicillin was introduced into clinical
use, MRSA isolates were reported worldwide [1].
The evolution and dissemination of MRSA, and
its control, are signiﬁcant problems in hospitals,
with overall higher costs being associated
with MRSA than with MSSA infection [21]. The
present study characterised the MRSA isolates
causing severe infectious diseases in a tertiary-
care hospital in Guadalajara, Mexico. One pre-
dominant multiresistant genotype constituted all
but one of the MRSA isolates investigated during
the 5-year study period (1999–2003). Antimicro-
bial resistance to several antibiotics, inclu-
ding b-lactams, was stable during the study. A
gradual decrease in susceptibility to vancomycin
was detected, which may be related to the fact
that vancomycin was an uncontrolled antibiotic in
the hospital and, from 1999, was the fourth most
24 Clinical Microbiology and Infection, Volume 12 Number 1, January 2006
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prescribed antibiotic. No vancomycin-resistant
S. aureus (VRSA) isolates were detected.
The single predominant MRSA clone (clone A)
found in the hospital showed 18 PFGE subtypes
(displaying up to six band differences) [22] and
belonged to ST5, spa type 2, SCCmec type II and
agr type 2. The SCCmec typing system is used to
distinguish between healthcare-associated MRSA
and community-acquired MRSA clones [23],
with most healthcare-associated MRSA isolates
harbouring SCCmec types I, II or III [3]. The
genes encoding enterotoxins G and I, c-haemo-
lysin variant and LukE–LukD leukotoxin were
detected in clone A MRSA isolates. LukE–LukD
toxin has been found in MRSA isolates from
patients with antibiotic-associated diarrhoea and
Fig. 2. Dendrogram comparing MRSA clone A (47MEXU) from the Hospital Civil de Guadalajara ‘Fray Antonio Alcalde’,
Mexico with different international MRSA clones (BK2464 (New York) and 78 MEXC (Mexico); New York ⁄ Japan clone;
EMRSA-16 clone; HPV107, Iberian clone; HU25, Brazilian clone). Patterns were clustered by the unweighted pair-group
method using arithmetic averages, and the similarity coefﬁcients were generated from a similarity matrix calculated with
the Jaccard coefﬁcient.
Table 1. Phenotypic and genotypic characteristics of a
single predominant clone (clone A) from a tertiary-care
hospital in Guadalajara, Mexico (1999–2003)
Antimicrobial resistance Penicillin, oxacillin, amoxycillin, cefotaxime,
cephalothin, cefazolin, imipenem, ciproﬂoxacin,
chloramphenicol, clindamycin, erythromycin,
clarithromycin, and tetracycline (except for two
isolates)
Antimicrobial susceptibility Gentamicin, trimethoprim–sulphamethoxazole,
rifampicin and vancomycin
PFGE pattern A-A18
spa type 2 (TJMBMDMGMK)
Sequence type (MLST) 5
SCCmec type II
agr type 2
Virulence genesa
seg +
sei +
hlg-v +
lukE–lukD +
aVirulence genes absent in all isolates (PVL, hlb, hlg, tst, edinAC, eta, etb, etd, sea, seb,
sec, sed, see, she, sej, sek, sel and sem) are not shown.
+, presence of toxin gene.
Fig. 1. Examples of pulsed-ﬁeld gel electrophoresis proﬁles obtained for MRSA isolates from the Hospital Civil of
Guadalajara ‘Fray Antonio Alcalde’, Mexico. Lanes: 1 and 24, lambda ladder used as molecular size (MW) markers; 2 and
23, reference strain NCTC8325; 3 (47MEXU) pattern A; 4–21, subtypes of clone A (A1–A18); 22 (122MEXU) pattern J.
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in MSSA strains causing impetigo [24]. Accord-
ing to Dufour et al. [25], the lukE–lukD genes
are found in approximately two-thirds of
S. aureus isolates from patients with all types of
staphylococcal infection, and these genes do not
appear to be associated with a speciﬁc type of
infection.
When compared with international clones
characterised previously, clone A showed a high
degree of similarity in MLST type, spa type,
PFGE pattern and SCCmec type to isolates
belonging to a clone (designated clone C) from
a Mexican paediatric hospital (Fig. 2), indica-
ting that this clone circulates in at least two
hospitals in Mexico located 540 km apart. This
clone emerged in 2001 in the paediatric hospital
and totally replaced a more susceptible clone
that predominated from 1997 until 2001 [26]. The
combination of characteristics suggested strongly
that this Mexican clone was very similar to the
multiresistant New York ⁄ Japan clone, described
initially in New York and Tokyo, which is now
widespread in the USA [27–29] and in other
regions of the world [30]. It also has similarities
to the vancomycin-intermediate S. aureus Mu50
strain isolated in 1997 from the pus of a Japanese
male baby with a surgical wound infection that
did not respond to vancomycin [31], and to the
ﬁrst two high-level VRSA isolates recovered in
the USA [28,32]. Thus, clone A belongs to the
New York ⁄ Japan lineage, and might have been
transferred from the USA to Mexico. MRSA
isolates with reduced susceptibility to vancomy-
cin have appeared in all ﬁve pandemic MRSA
lineages [28,33]. However, at least two of the
three VRSA isolates belong to the New York ⁄
Japan clone (ST5-II), reinforcing the need to
continue surveillance of clone A isolates with
decreased susceptibility to vancomycin.
Molecular typing techniques allow the identi-
ﬁcation of pandemic clones of MRSA, and
enable monitoring of MRSA clones circulating in
different hospitals and at different time-intervals
in a country [4,28]. The identiﬁcation of well-
deﬁned groups of isolates with a common
genetic background gives a basis for further
understanding the distribution of virulence
genes, or the dissemination of particular clones
in the hospital environment, and will help to
prevent dissemination of MRSA. These tech-
niques should help to predict the emergence
of new and even more serious strains of
multiresistant bacteria (e.g., VRSA), and will
enable the establishment of international policy
guidelines that will aid countries in preventing
the global spread of any newly emerging multi-
resistant bacterial pathogen.
Coexistence of MRSA is usual in the nosoco-
mial setting. For example, the New York ⁄ Japan
clone, together with EMRSA-16 and New York
clone V, were the prevalent clones in two
hospitals in Miami, USA [27,28]. Replacement
of MRSA clones over time in a hospital is also
frequent. Interestingly, many countries are
experiencing the introduction of, and even
replacement of multiresistant MRSA clones by,
more susceptible clones harbouring SCCmec type
IV [34,35]. The present study detected a single
multiresistant clone among the selected 216
isolates, which represented 26% of the total
MRSA isolates recovered in the hospital during
the 5-year study period. This predominant clone
displayed 18 PFGE subtypes; similarly, 40 sub-
types were reported for 132 MRSA isolates
belonging to the New York ⁄ Japan clone that
were recovered in a single year in a hospital in
Tokyo, Japan [20]. The successful adaptation of
pandemic clones in many different hospital
ecosystems may explain a greater tendency to
generate the genetic variability observed. The
epidemic capacity of this particular international
pandemic MRSA clone was demonstrated by the
way in which it completely replaced a previous
clone, prevalent for at least 4 years, in a paedia-
tric hospital in Mexico [26].
As demonstrated by Kotilainen et al. [36], con-
trolling or even eliminating MRSA in the hospital
environment is possible if strict measures, inclu-
ding continuous staff education, contact isolation
for MRSA-positive patients, systematic screening
for persons exposed to MRSA, and cohort nursing
of MRSA-positive and MRSA-exposed patients in
epidemic situations, are taken systematically
before the organism becomes endemic. However,
institutions, such as the hospital in the present
study, that suffer from overcrowding, high work-
loads, staff shortages and poor adherence to hand
hygiene guidelines will have difﬁculties in
controlling endemic MRSA clones [37,38]. More-
over, those attempting control should also take
into consideration the pressure caused by the
inappropriate use of antibiotics in hospitals in
Mexico, and their efforts should conform strictly
with published guidelines.
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